Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Nrf2 Plays a Protective Role Against Intravascular Hemolysis-Mediated Acute Kidney Injury

  • Rubio-Navarro, Alfonso
  • Vázquez-Carballo, Cristina
  • Guerrero-Hue, Melania
  • García-Caballero, Cristina
  • Herencia, Carmen
  • Gutiérrez, Eduardo
  • Yuste, Claudia
  • Sevillano, Ángel
  • Praga, Manuel
  • Egea, Javier
  • Cannata, Pablo
  • Cortegano, Isabel
  • Andres, Belen de
  • Gaspar, Maria Luisa
  • Cadenas, Susana
  • Michalska, Patrycja
  • León, Rafael
  • Ortiz, Alberto
  • Egido, Jesús
  • Moreno, Juan Antonio
Massive intravascular hemolysis is associated with acute kidney injury (AKI). Nuclear factor erythroid-2-related factor 2 (Nrf2) plays a central role in the defense against oxidative stress by activating the expression of antioxidant proteins. We investigated the role of Nrf2 in intravascular hemolysis and whether Nrf2 activation protected against hemoglobin (Hb)/heme-mediated renal damage in vivo and in vitro. We observed renal Nrf2 activation in human hemolysis and in an experimental model of intravascular hemolysis promoted by phenylhydrazine intraperitoneal injection. In wild-type mice, Hb/heme released from intravascular hemolysis promoted AKI, resulting in decreased renal function, enhanced expression of tubular injury markers (KIM-1 and NGAL), oxidative and endoplasmic reticulum stress (ER), and cell death. These features were more severe in Nrf2-deficient mice, which showed decreased expression of Nrf2-related antioxidant enzymes, including heme oxygenase 1 (HO-1) and ferritin. Nrf2 activation with sulforaphane protected against Hb toxicity in mice and cultured tubular epithelial cells, ameliorating renal function and kidney injury and reducing cell stress and death. Nrf2 genotype or sulforaphane treatment did not influence the severity of hemolysis. In conclusion, our study identifies Nrf2 as a key molecule involved in protection against renal damage associated with hemolysis and opens novel therapeutic approaches to prevent renal damage in patients with severe hemolytic crisis. These findings provide new insights into novel aspects of Hb-mediated renal toxicity and may have important therapeutic implications for intravascular hemolysis-related diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Sodium-glucose cotransporter 2 inhibition, towards an indication to treat diabetic kidney disease

  • Górriz, Jose Luis|||0000-0002-1134-9051
  • Navarro-González, Juan F.|||0000-0002-5015-7474
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Vergara, Ander|||0000-0003-1926-0147
  • Núñez, Julio|||0000-0003-1672-7119
  • Jacobs-Cachá, Conxita|||0000-0003-2518-7847
  • Martínez-Castelao, Alberto
  • Soler, María José|||0000-0003-3621-0766
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have clearly demonstrated their beneficial effect in diabetic kidney disease (DKD) on top of the standard of care [blood glucose control, renin-angiotensin system blockade, smoking cessation and blood pressure (BP) control], even in patients with overt DKD. However, the indication of this drug class is still blood glucose lowering in type 2 diabetic patients with estimated glomerular filtration rate >45 mL/min/1.73 m 2. Based on the new evidence, several scientific societies have emphasized the preferential prescription of SGLT2i for patients at risk of heart failure or kidney disease, but still within the limits set by health authorities. A rapid positioning of both the European Medicines Agency and the US Food and Drug Administration will allow patients with overt DKD to benefit from SGLT2i. Clinical experience suggests that SGLT2i safety management may in part mirror renin-angiotensin blockade safety management in patients with overt DKD. This review focuses on the rationale for an indication of SGTL2i in DKD. We further propose clinical steps for maximizing the safety of SGLT2i in DKD patients on other antidiabetic, BP or diuretic medication.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Podocyturia, why it may have added value in rare diseases

  • Sánchez Niño, María Dolores
  • Pérez-Gómez, Maria Vanessa|||0000-0003-4558-5236
  • Valiño-Rivas, Lara
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Ortiz, Alberto|||0000-0002-9805-9523
Fabry disease is an inherited lysosomal disease in which defects in the GLA gene lead to α-galactosidase-A deficiency, and accumulation of glycosphingolipids, including lyso-Gb3, a podocyte stressor. Therapy is available as enzyme replacement therapy and, for some patients, the chaperone migalastat. A key decision is when to start therapy, given its costs and potential impact on some aspects of quality of life. The decision is especially difficult in otherwise asymptomatic patients. A delayed start of therapy may allow kidney injury to progress subclinically up to the development of irreversible lesions. Non-invasive tools to monitor subclinical kidney injury are needed. One such tool may be assessment of podocyturia. In this issue of CKJ, [Trimarchi H, Canzonieri R, Costales-Collaguazo C et al. Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytes. Clin Kidney J 2019; doi.org/10.1093/ckj/sfy053] report on podocyturia assessment in Fabry nephropathy. Specifically, they report that podocalyxin may be lost from detached urinary podocytes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MYH9-related disease, it does exist, may be more frequent than you think and requires specific therapy

  • Fernandez-Prado, Raul
  • Carriazo-Julio, Sol Maria
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Pérez-Gómez, Maria Vanessa|||0000-0003-4558-5236
In this issue of ckj, Tabibzadeh et al. report one of the largest series of patients with MYH9 mutations and kidney disease. The cardinal manifestation of MYH9-related disease is thrombocytopenia with giant platelets. The population frequency of pathogenic MYH9 mutations may be at least 1 in 20 000. The literature abounds in misdiagnosed cases treated for idiopathic thrombocytopenic purpura with immune suppressants and even splenectomy. Additional manifestations include neurosensorial deafness and proteinuric and hematuric progressive kidney disease (at some point, it was called Alport syndrome with macrothrombocytopenia), leucocyte inclusions, cataracts and liver enzyme abnormalities, resulting in different names for different manifestation combinations (MATINS, May-Hegglin anomaly, Fechtner, Epstein and Sebastian syndromes, and deafness AD 17). The penetrance and severity of kidney disease are very variable, which may obscure the autosomal dominant inheritance. A correct diagnosis will both preclude unnecessary and potentially dangerous therapeutic interventions and allow genetic counselling and adequate treatment. Morphological erythrocyte, granulocyte and platelet abnormalities may allow the future development of high-throughput screening techniques adapted to clinical peripheral blood flow cytometers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Podocyte and tubular involvement in AngioJet-induced kidney injury

  • Esteras, Raquel
  • Cannata-Ortiz, Pablo
  • del Palacio-Tamarit, Marta
  • Guerrero-Hue, Melania
  • García-Caballero, Cristina
  • Egido, Jesús
  • Gimeno Beltran, Javier|||0000-0001-6085-5228
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Gracia-Iguacel, Carolina
  • Moreno Gutiérrez, Juan Antonio|||0000-0002-7468-2871
The AngioJet technique combines localized thrombolysis and percutaneous mechanical thrombectomy (PMT). However, PMT may cause acute kidney injury (AKI), which has been ascribed to severe mechanical haemolysis, although no renal biopsies have been reported. We now report the first renal biopsy in a patient with AKI following PMT. There is histological evidence of haemoglobin (Hb)-induced tubular injury and podocyte stress characterized by intracellular Hb and staining for ferritin and hemo-oxygenase-1, suggestive of an adaptive response to oxidative stress. This confirms that Hb is involved in kidney cell injury and supports the existence of several different kidney cellular targets.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Hunger and satiety peptides, is there a pattern to classify patients with prader-willi syndrome?

  • Bueno, Marta|||0000-0001-9488-4553
  • Boixadera Planas, Ester|||0000-0002-3995-6750
  • Blanco Hinojo, Laura, 1981-
  • Esteba-Castillo, Susanna|||0000-0003-0414-0599
  • Giménez-Palop, Olga|||0000-0002-4526-6342
  • Torrents-Rodas, David|||0000-0003-0222-7770
  • Pujol Nuez, Jesús|||0000-0002-9946-4547
  • Corripio, Raquel|||0000-0003-3344-8269
  • Deus Yela, Juan|||0000-0002-3305-2662
  • Caixàs i Pedragós, Assumpta|||0000-0001-8472-9189
Hyperphagia is one of the main problems of patients with Prader-Willi syndrome (PWS) to cope with everyday life. The underlying mechanisms are not yet well understood. Gut-brain hormones are an interrelated network that may be at least partially involved. We aimed to study the hormonal profile of PWS patients in comparison with obese and healthy controls. Thirty adult PWS patients (15 men; age 27.5 ± 8.02 years; BMI 32.4 ± 8.14 kg/m), 30 obese and 30 healthy controls were studied before and after eating a hypercaloric liquid diet. Plasma brain-derived neurotrophic factor (BDNF), leptin, total and active ghrelin, peptide YY (PYY), pancreatic polypeptide (PP), Glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and amylin were determined at times 0, 30, 60 and 120. Cluster analysis was used. When considering all peptides together, two clusters were established according to fasting hormonal standardized concentrations. Cluster 1 encompassed most of obese (25/30) and healthy controls (28/30). By contrast, the majority of patients with PWS were located in Cluster 2 (23/27) and presented a similar fasting profile with hyperghrelinemia, high levels of leptin, PYY, GIP and GLP-1, compared to Cluster 1; that may reflect a dysfunction of these hunger/satiety hormones. When peptide behavior over the time was considered, PP concentrations were not sustained postprandially from 60 min onwards in Cluster 2. BDNF and amylin did not help to differentiate the two clusters. Thus, cluster analysis could be a good tool to distinguish and characterize the differences in hormone responses between PWS and obese or healthy controls.